NCT05467202尚未招募1 期
To Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Zhejiang University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Evaluation of Safety
研究概览
简要总结
This is an open label, phase I study to assess the safety and efficacy of CLL1 CAR-T in patients with relapsed and refractory acute myeloid leukemia
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities;
- •Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML);
- •The expression of CLL1 in AML blast is positive ;
- •The patient has recovered from the toxicity of previous treatment;
- •ECOG score ≤ 2 and expected survival period is not less than 3 months;
- •Adequate organ function defined as:
- •AST ≤3×ULN; ALT ≤3×ULN; Total bilirubin ≤1.5×ULN; Serum creatinine ≤1.5×ULN, or CCR≥60 mL/min; Hemoglobin ≥60g/L ; Indoor oxygen saturation ≥92%; LVEF≥45%;
- •Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test;
- •From the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception
排除标准
- •Diagnosis of acute promyelocytic leukemia;
- •History or presence of a CNS disorder;
- •HBsAg or HBcAb are positive; HCV 、HIV and Syphilis antibody are positive, CMV DNA in peripheral blood is more than≥500 copies /mL;
- •History of severe hypersensitivity reaction;
- •History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment;
- •History of organ transplant surgery;
- •Required systemic application of immunosuppressive or other drugs;
- •Auto-SCT within the 3 months before enrollment;
- •Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES));
- •Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) ;
- •Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management;
- •Live vaccine received within the ≤ 4 weeks before enrollment;
- •Persons with serious mental illness;
- •History of major surgical operations four weeks before enrollment;
- •History of alcoholism or substance abuse;
- •Was identified by the investigators as unsuitable to participate in the study
研究组 & 干预措施
Treatment group
Experimental
Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.
Dose Expansion:Participants receive a single dose (at the MTD determined).
干预措施: CLL1 CAR-T (Drug)
结局指标
主要结局
Evaluation of Safety
时间窗: Up to 2 years after CLL1 CAR-T infusion
Count the Incidence of adverse events
Changes in cytokine level after CLL1 CAR-T infusion
时间窗: Up to 2 years after CLL1 CAR-T infusion
Calculate the change of cytokine level in peripheral blood by flow cytometry after CLL1 CAR-T infusion. Cytokines include IL-2、IL-6、IL-10、IFN-γ.
次要结局
- Complete response rate(CRR)(Up to 2 years after CLL1 CAR-T infusion)
- Partial response Rate (PRR)(Up to 2 years after CLL1 CAR-T infusion)
- Overall response Rate(ORR)(Up to 2 years after CLL1 CAR-T infusion)
研究者
He Huang
Professor
Zhejiang University
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological MalignanciesAMLNCT05252572Zhejiang University36
尚未招募
1 期
Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AMLAMLNCT05467254Zhejiang University20
招募中
1 期
ThisCART19A Bridging to alloHSCT for R/R B-ALLCARRefractory Acute Lymphoblastic LeukemiaRelapsed Adult ALLNCT05679687The First Affiliated Hospital of Soochow University20
终止
1 期
A Study to Investigate LYL797 in Adults With Solid TumorsTriple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Advanced Lung CarcinomaNSCLC, RecurrentNSCLC Stage IVRelapsed CancerRelapse/RecurrenceRecurrent Breast CancerRecurrent NSCLCPlatinum-resistant Ovarian CancerFallopian Tube CancerEndometrial CancerEndometrioid TumorOvarian CancerNSCLCHigh Grade Serous CarcinomaOvarian Epithelial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung CancerAdvanced Breast CancerNCT05274451Lyell Immunopharma, Inc.57
招募中
1 期
CLL-1 CAR-NK Cells for Relapsed/Refractory AMLRelapsed Adult AMLRefractory AMLNCT06307054Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine24